December 10, 2010 01:20 ET
Spinal Cord Injury Patient Treated With Non-Matched Adult Stem Cells
Medistem Reports First Human Use of Universal Donor Combination Adult Stem Cell Therapy in Spinal Cord Injury
SAN DIEGO, CA--(Marketwire - December 10, 2010) - Medistem Inc. (PINKSHEETS: MEDS) announced today peer-reviewed publication of its data on what is believed to be the first "combination therapy" adult stem cell protocol for spinal cord injury.
The patient treated, who was 29 years old at the time, suffered a spinal cord injury resulting from an airplane crash on May 13th of 2008. He had no walking ability, intermittent pain and loss of sexual function. The patient was injected with a combination universal donor stem cell therapy in November of 2008, and January and July of 2009. A gradual improvement was observed subsequent to each administration of stem cells.
Currently the patient has recovered sexual function, is walking, and has a dramatic reduction in pain symptoms.
The medical article describing the procedure was published in the peer-reviewed journal International Archives of Internal Medicine and was co-authored by scientists at the University of California San Diego, Indiana University, and University of Utah. It can be accessed at this link: http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf.
"While we cannot make any conclusions based on the treatment of only one patient, we are very excited to see such a drastic improvement," said Dr. Bogin, Chairman and President of Medistem.
Medistem is an adult stem cell company based in San Diego, California. The company has filed an Investigational New Drug Application (IND) with the FDA for use of its universal donor endometrial regenerative cells (ERC) for treatment of critical limb ischemia, an advanced form of peripheral artery disease. The Endometrial Regenerative Cells may be purchased for research use at the General Biotechnology LLC website: http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
"We aim to initiate clinical trials in the US in the first quarter of 2011. Through this we hope to take data from promising case reports, such as the one discussed today, into the scientific framework required by the FDA for going down the path to full registration," said Dr. Sablin, Vice President of Medistem, who is also founder of Selena Pharmaceuticals and co-founder of the NASDAQ company Medivation Inc. "The fact that Endometrial Regenerative Cells can be made into lung, liver, brain, pancreatic, bone, fat, blood vessel, heart, and muscle tissue suggests that these cells may be useful for numerous diseases."
"To date we have published patient results in multiple sclerosis, heart failure, Duchenne Muscular Dystrophy, and now spinal cord injury," said Mr. Zaharchook, Vice Chairman and Board Member of the Company. "While we as a company are focused on our critical limb ischemia program, we are optimistic about the other clinically-applicable uses of the ERC and are currently seeking strategic partners."
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.